Micafungin Teva (Micafungin)

Micafungin inhibits the fungal enzyme β-(1,3)-D-glucan synthase, which is required for the synthesis of β-(1,3)-D-glucan, an essential component of the fungal cell wall. By disrupting cell‑wall formation, the drug causes osmotic instability and leads to fungal cell death.

The dosage of Micafungin Teva is determined by the prescribing healthcare professional based on the specific indication, patient weight, renal and hepatic function, and other clinical factors. Only a qualified prescriber should set the appropriate dosing regimen.

Safety data for micafungin in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To order Micafungin Teva, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Micafungin belongs to the echinocandin class, which differs from azole antifungals such as fluconazole. Echinocandins target the fungal cell wall, offering a fungicidal effect and a lower risk of drug‑drug interactions with CYP enzymes, whereas azoles inhibit ergosterol synthesis and may have more extensive hepatic metabolism and interaction profiles.

Micafungin Teva should be stored at 2‑8 °C (refrigerated). Keep the solution in its original container, protect it from light, and avoid freezing or shaking. If the product must be transported, maintain the cold‑chain conditions throughout the journey.

Micafungin is given as an intravenous infusion. The infusion is typically administered over a period of 30‑60 minutes, depending on the clinical protocol and patient tolerance. Administration should be performed by qualified healthcare personnel in a setting equipped for IV therapy.

The most serious adverse events include hepatotoxicity (significant liver injury), severe hypersensitivity reactions such as anaphylaxis, and infusion‑related reactions that may cause hypotension, respiratory distress, or chest pain. Patients should be monitored closely for these events during and after infusion.

Micafungin is contraindicated in individuals with a known hypersensitivity to micafungin or any component of the formulation. Caution is also advised for patients with severe hepatic impairment, as liver dysfunction may increase the risk of toxicity. The drug should be avoided in such cases unless the prescriber determines that benefits outweigh risks.